Biostrap To Partner With Leading Pediatric Hospital To Develop Biomarker For Sickle Cell Disease

On January 12, 2021, Cision PRWeb reported that Biostrap To Partner With Leading Pediatric Hospital To Develop Biomarker For Sickle Cell Disease

Monitoring and detecting changes in blood flow through Biostrap’s high-resolution PPG data capture, researchers at Children’s Hospital Los Angeles are confident the biomarker can make a difference in the pain management for patients with sickle cell disease.

The power of raw waveform photoplethysmography (PPG) in wearable technology now allows researchers to monitor patients’ health in the comfort of their home without sacrificing data reliability.

Not all wearables are made equal though. Most discard 90% of that data to ease customer usability. A clinically reliable health monitoring platform called Biostrap, on the other hand, uses raw PPG as its superpower to help advance science. Collaborating with Biostrap and utilizing its wrist-worn device’s data capture, researchers at Children’s Hospital Los Angeles (CHLA) are working on developing a new physiological biomarker to detect the autonomic vascular dysfunction of sickle cell disease patients.

“We are really excited about this collaboration with CHLA,” said Sameer Sontakey, CEO at Biostrap. “We’ve always believed in the power of PPG. There’s so much knowledge embedded deep into it, and the biomarker CHLA researchers are developing shows the beauty of what PPG has to offer to the world.“

The seriousness of this genetic disease varies among patients and no readily available cure currently exists. A common complication; however, is musculoskeletal pain due to obstruction of blood flow in the microcirculation that may even prompt hospitalization.

To read the full article click here.